Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 18.47% is 19% below its 5-year average of 22.74%, near the high end of its 5-year range (-62.32%–30.78%).
4.61% above its 12-month average of 17.66%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2.36%.
EBITDA MARGIN
18.47%
EBITDA MARGIN AVG TTM
17.66%
EBITDA MARGIN AVG 3Y
23.32%
EBITDA MARGIN AVG 5Y
22.74%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.61%
CURRENT VS 3Y AVG
-20.79%
CURRENT VS 5Y AVG
-18.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AdaptHealth Corp.
Market Cap
$789.11M
EBITDA Margin
18.47%
TTM Avg
17.66%
3Y Avg
23.32%
5Y Avg
22.74%
Market Cap
$783.77M
EBITDA Margin
12.02%
TTM Avg
14.44%
3Y Avg
-4.83%
5Y Avg
-238.26%
Market Cap
$807.78M
EBITDA Margin
-9.31%
TTM Avg
-8.54%
3Y Avg
-46.73%
5Y Avg
-472.39%
Market Cap
$773.03M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
Market Cap
$766.63M
EBITDA Margin
16.77%
TTM Avg
16.87%
3Y Avg
-15.22%
5Y Avg
-3.72%
Market Cap
$764.02M
EBITDA Margin
-96.96%
TTM Avg
-364.73%
3Y Avg
-21782.60%
5Y Avg
-19407.37%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AdaptHealth Corp. (AHCO) | $789.11M | 18.47% | 17.66% | 23.32% | 22.74% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $783.77M | 12.02% | 14.44% | -4.83% | -238.26% |
| Ardelyx, Inc. (ARDX)vs › | $807.78M | -9.31% | -8.54% | -46.73% | -472.39% |
| InMode Ltd. (INMD)vs › | $805.85M | 23.23% | 25.96% | 33.88% | 36.34% |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $773.03M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| Mesa Laboratories, Inc. (MLAB)vs › | $766.63M | 16.77% | 16.87% | -15.22% | -3.72% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $764.02M | -96.96% | -364.73% | -21782.60% | -19407.37% |
| Jade Biosciences, Inc. (JBIO)vs › | $819.78M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $827.61M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
Gross Margin
10.4%
EBITDA Margin
18.5%
Operating Margin
-0.3%
Net Margin
-7.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2.36% |
| 2026-04-10 | 15.15% |
| 2025-12-31 | 17.94% |
| 2025-09-30 | 27.35% |
| 2025-06-30 | 30.20% |
| 2025-03-31 | 20.24% |
| 2024-12-31 | 21.97% |
| 2024-09-30 | 25.81% |
| 2024-06-30 | 24.07% |
| 2024-03-31 | 24.14% |
| 2023-12-31 | -8.49% |
| 2023-09-30 | -62.32% |
| 2023-06-30 | 26.31% |
| 2023-03-31 | 17.31% |
| 2022-12-31 | 9.51% |
| 2022-09-30 | 26.05% |
| 2022-06-30 | 26.10% |
| 2022-03-31 | 24.51% |
| 2021-12-31 | 20.84% |
| 2021-09-30 | 30.78% |
| 2021-06-30 | 20.94% |
| 2021-03-31 | 12.99% |
| 2020-12-31 | 16.33% |
| 2020-09-30 | 12.66% |
| 2020-06-30 | 14.62% |
| 2020-03-31 | 13.04% |
| 2019-12-31 | 0.90% |
| 2019-09-30 | 11.45% |
| 2019-06-30 | -0.88% |
| 2019-03-31 | 12.24% |
| 2018-12-31 | 13.24% |
| 2018-09-30 | 12.78% |
| 2018-06-30 | 14.16% |
| 2018-03-31 | 14.40% |
